Medix planning Mexican NDA for obesity candidate

Saniona AB (SSE:SANION) said partner Medix Products S.A. de C.V. (Mexico City, Mexico) plans to submit an NDA next half in Mexico for obesity candidate tesofensine (NS2330) after two doses of the compound met the primary endpoint of reducing body weight from baseline to week 24 vs. placebo in the Phase III VIKING trial in the indication (p<0.001).

The double-blind, Mexican trial enrolled 372 obese patients to receive placebo or once-daily 0.25 or 0.5 mg oral tesofensine. On the primary endpoint, Saniona said tesofensine led to an average weight loss of 10% in 24 weeks. Additionally, more than half of patients who received tesofensine achieved weight loss of at least 10%...